Volume 2 Supplement 2

Abstracts from the 1st Immunotherapy of Cancer Conference (ITOC1)

Open Access

S75. KEYNOTE LECTURE: Basic concept for the understanding of cancer mediated immune rejection

  • F Marincola1 and
  • E Wang2
Journal for ImmunoTherapy of Cancer20142(Suppl 2):I13

https://doi.org/10.1186/2051-1426-2-S2-I13

Published: 12 March 2014

Background

Cancer is a multi-genic, complex biological phenomenon and its growth is affected by various categories of factors including the genetics of the host, the accumulating genetic alteration within cancer cells and environmental modifiers.

Material and methods

Therefore, to identify the determinants of immune-mediated tumor rejection during immunotherapy, a systematic and comprehensive monitoring approach needs to be applied that covers the various categories at a time relevant to the therapeutic intervention. In addition, a temporal dimension needs to be added to evaluate in real time the changes induced by treatment and their relationship with clinical outcome.

Results

In this presentation, we will review the salient concepts that should guide the future monitoring of clinical trials taking advantage of novel and comprehensive technological advances presenting examples of integrated approaches for the assessment of patients' response to adoptive T cell therapy.

Conclusions

Our experience highlights the need to apply multi-parametric approaches for the understanding of the mechanism(s) leading to cancer rejection by the immune system in humans.

Authors’ Affiliations

(1)
Sidra Medical and Research Center
(2)
Sidra Medical and Research Center, Research Branch

Copyright

© Marincola and Wang; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement